Q-omics provides the consensus-scored TPTE2P6 profile across patient tissues and cancer cell-line models. TPTE2P6 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TPTE2P6 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, TPTE2P6 RNA expression shows 13,806 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KICH, and UVM as cancer lineages where TPTE2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPTE2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPTE2P6 survival associations across molecular data types. TPTE2P6 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPTE2P6 RNA expression–survival associations across cancer types. High TPTE2P6 expression shows unfavorable associations in UCEC, UVM, KIRP and KICH, but favorable associations in LGG and LIHC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for TPTE2P6 RNA expression.
This table summarizes TPTE2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TPTE2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPTE2P6 shows lower tumor expression in KICH and BRCA. The KICH box plot shows higher TPTE2P6 RNA expression in normal versus tumor tissue (log2 FC = −0.028, t-test p = .012).
This table shows molecular features associated with TPTE2P6 in patient tissues and cancer cell lines. In patient samples, TPTE2P6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TPTE2P6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
